Company Overview
Snapshot
Founded in December 2001 by Chuck (Shahak) Cohen, Solio Therapy operates with 1–10 employees. The company focuses on developing advanced pain relief technologies. A key milestone for the company was securing FDA clearance for its Alfa Plus device in July 2019.
Business overview
Solio Therapy specializes in advanced technologies for pain relief and therapeutic treatments within the Health Tech & Life Sciences sector. The company's core product, the Solio Alfa Plus, is an FDA- and CE-approved radio frequency (RF) home device designed to alleviate chronic pain, pain from trauma, sports injuries, and menstruation. This non-invasive technology uses deep heat from four RF diodes to increase blood circulation, accelerate tissue regeneration, and reduce inflammation, muscle aches, stiffness, and pain, serving patients globally.
Strategic signal
In July 2019, Solio Therapy's Alfa Plus device received FDA clearance. This regulatory approval is a significant validation of the device's safety and efficacy, opening up the US market for the company's radio frequency-based pain relief solution. For investors, this signals a critical step towards broader commercialization and market penetration in the competitive medical device landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is Solio Therapy's primary focus?
- Solio Therapy focuses on developing RF energy-based solutions for pain relief, offering advanced technologies in user-friendly devices for home use.
- When was Solio Therapy founded?
- Solio Therapy was founded in December 2001.
- Who founded Solio Therapy?
- Solio Therapy was founded by Chuck (Shahak) Cohen.
- What is the Solio Alfa Plus device?
- The Solio Alfa Plus is an FDA- and CE-approved radio frequency (RF) home device designed for pain relief, utilizing deep heat to increase blood circulation and reduce inflammation.
- When did the Solio Alfa Plus receive FDA clearance?
- The Alfa Plus by Solio received FDA clearance in July 2019.